Aktis Oncology, Inc. (AKTS) vs Bioventus Inc. (BVS)
A side-by-side comparison of Aktis Oncology, Inc. and Bioventus Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.52HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
BVS
Bioventus Inc.
$13.52HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AKTS vs BVS
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)BVS +69.0% (+69.0%/yr)BVS compounded faster over this window
AKTS BVS
AKTS vs BVS: by the numbers
- •AKTS is the larger company ($989M vs $916M market cap).
- •BVS is profitable (9.36% net margin) while AKTS runs a net loss (-727.04%).
Metrics side by side
Valuation
| Metric | AKTS | BVS |
|---|---|---|
| P/E ratio | N/A | 17.55 |
| Forward P/E | N/A | 17.36 |
| P/S ratio | 98.32 | 1.57 |
| P/B ratio | 2.04 | 4.01 |
| EV / EBITDA | N/A | 10.74 |
| FCF yield | N/A | 10.29% |
Profitability
| Metric | AKTS | BVS |
|---|---|---|
| Gross margin | 100.00% | 68.00% |
| Operating margin | -1149.52% | 10.63% |
| Net margin | -727.04% | 9.36% |
| ROE | -15.09% | 23.86% |
| ROIC | -16.54% | 11.37% |
Growth (annualized)
| Metric | AKTS | BVS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 11.82% |
| EPS CAGR (5Y) | N/A | -5.03% |
| FCF CAGR (5Y) | N/A | 43.36% |
| Total return CAGR (5Y) | N/A | -0.81% |
Frequently asked
- Is AKTS or BVS more profitable?
- BVS runs the higher net margin — AKTS at -727.04% versus BVS at 9.36%.
Go deeper
Dig into the metrics
Bioventus P/E ratioAktis Oncology ROEBioventus ROEAktis Oncology operating marginBioventus operating marginAktis Oncology revenue growthBioventus revenue growthAktis Oncology free cash flowBioventus free cash flow
Aktis Oncology & Bioventus appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.